Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy

Status Completed

Clinical Trial Summary

Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality.

Clinical Trial Description

Patients affected by CLMs and trated with neoadjuvant systemic chemotherapy and then hepatectomy were reviewed with the intent to assess the occurrence of liver atrophy, which is a sign of liver dysfunction and a source of morbidity expecially in patients treated with major or extended hepatectomy. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. Then, we planned to review our cases with the above mentioned endpoint. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06329700
Study type	Observational
Source	Azienda Ospedaliero Universitaria Maggiore della Carita
Contact
Status	Completed
Phase
Start date	May 1, 2010
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03594448` - Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Active, not recruiting	`NCT03986541` - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Completed	`NCT01570452` - Matrilysin Expression in Different Stages of Colorectal Tumors	N/A
Recruiting	`NCT05354817` - Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin	Phase 2
Recruiting	`NCT05576896` - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory	Phase 2
Completed	`NCT04715061` - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments	N/A
Terminated	`NCT03149679` - The p53 Colorectal Cancer Trial	Phase 2
Completed	`NCT05550701` - Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
Enrolling by invitation	`NCT04149613` - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed	`NCT04425239` - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT05382741` - Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	Phase 2
Recruiting	`NCT06342440` - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting	`NCT04917276` - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting	`NCT06296056` - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care	Phase 1
Recruiting	`NCT04714814` - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting	`NCT05451719` - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy	Phase 2
Completed	`NCT03031444` - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis	Phase 2/Phase 3
Completed	`NCT05164419` - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting	`NCT05171660` - Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer	Phase 3
Recruiting	`NCT05426005` - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer	Phase 1/Phase 2